What Medicare Datasets Reveal About Care, Referrals, and Costs
CareSet’s DocGraph and federal hospital cost reports are providing new empirical insights into how policy changes, provider relationships and financial reporting play […]
What we’re seeing in the data, the policy environment, and the field.
Analysis written when the data has something worth saying. We publish based on substance rather than volume, for pharmaceutical commercial teams, policy audiences, and the public interest community.
Featured Article
Research Library
Original research from CareSet’s complete Medicare Fee-for-Service claims, for pharmaceutical commercial teams, policy audiences, and the public interest community.
Did CAR-T’s moment pass?
Leveraging complete census-level access to monthly Medicare claims, CareSet analyzed datafrom April 2023 to October 2024 to uncover insights into CAR-T and […]
Get the White Paper → CAR-T and Bispecific White Paper
Introduction: Eighteen months ago, CareSet published Did CAR-T’s moment pass?, an analysis of Medicare claims from April 2023 through October 2024. That […]
Get the White Paper → Latest Articles
What Medicare Datasets Reveal About Care, Referrals, and Costs
CareSet’s DocGraph and federal hospital cost reports are providing new empirical insights into how policy changes, provider relationships and financial reporting play […]
As RPM Use Soars, CMS Proposes Tighter Rules for Third-Party Vendors
CMS proposed to ban third-party vendors from providing remote patient monitoring services (RPM) and remote therapeutic monitoring (RTM) services on behalf of […]
Revolution Medicines’ Breakthrough Drug Doubles Survival in Advanced Pancreatic Cancer
Revolution Medicines’ investigational drug daraxonrasib significantly extended survival for patients with previously treated metastatic pancreatic cancer, according to full results from its […]
ASCO 2026: New Data Highlight Advances in Prostate Cancer Treatments
New research presented at the 2026 ASCO Annual Meeting, held May 29 through June 2 in Chicago, showed that Nubeqa (darolutamide) was […]
ASCO 2026: Tecvayli Trial Shows Strong Survival Benefit in Multiple Myeloma
Among the most closely watched multiple myeloma presentations at the 2026 ASCO Annual Meeting was the phase 3 MajesTEC-9 trial, which found […]
CareSet Data Shows Billions in Medicare Fraud from Catheters
By Jinghong Chen In the span of just three months, a single Denver medical supply company submitted more than $1.13 billion in […]
